Liposome-containing diagnostic reagent as well as production method and application thereof

By using liposomes instead of latex beads, combined with analyte-specific binding elements and dyes, the complexity and risks of existing diagnostic immunoassay reagents are resolved, achieving simplified preparation and efficient detection, suitable for automated diagnostic testing instruments and point-of-care settings.

CN118901013APending Publication Date: 2024-11-05SIEMENS HEALTHCARE DIAGNOSTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380026077.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-08
Filing Date
2023-02-16
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing diagnostic immunoassay reagents suffer from problems such as high material and resource requirements, complex processes, difficulties in managing hazardous chemicals, and high waste disposal costs during preparation. In particular, the purification and functional stability requirements for transmembrane proteins such as thyroid-stimulating hormone receptor (TSHR) are high, which makes assay development difficult.

Method used

Using liposomes as an alternative to latex beads, the transmembrane domains of analyte-specific binding elements, such as receptor proteins, are anchored into the lipid bilayer of liposomes, exposing their extracellular domains for the detection of target analytes. Encapsulation or the inclusion of dyes can enhance detection performance, and multiplexing can be achieved through microfluidic devices.

Benefits of technology

It simplifies the reagent preparation process, reduces the use of hazardous chemicals, lowers waste disposal costs, improves detection sensitivity and multiplexing capabilities, simulates the natural membrane conditions of receptor proteins, and is suitable for automated diagnostic testing instruments and point-of-care settings.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118901013A_ABST
    Figure CN118901013A_ABST
Patent Text Reader

Abstract

A diagnostic immunoassay reagent composition comprising a liposome having an analyte-specific binding element associated therewith is disclosed. In particular, the analyte-specific binding element comprises a transmembrane domain that anchors the element in the lipid bilayer of the liposome; the analyte-specific binding element further comprises an extracellular / extracellular domain exposed on the outer surface of the liposome and comprising a domain that specifically binds to a target analyte. Also disclosed are kits, devices, and systems containing the diagnostic immunoassay reagent compositions, as well as methods of producing and using the diagnostic immunoassay reagent compositions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS / INCORPORATION BY REFERENCE STATEMENT

[0002] This application claims priority to U.S. Provisional Application No. 63 / 317,643, filed on March 8, 2022, the contents of which are incorporated herein by reference in their entirety.

[0003] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0004] not applicable. Background Art

[0005] In the field of medicine and clinical chemistry, many studies and determinations of physiologically active species or analytes are carried out by utilizing the interaction between specific binding pairs. For example, the target analyte in the patient sample can be a member of the specific binding pair, and the target analyte can be detected by using the corresponding member of the specific binding pair fixed to the solid support. For example (but not limited to), the fixed binding pair member can be an antigen for the target antibody in the detection sample or vice versa (that is, the fixed binding pair member can be an antibody for the target analyte in the detection sample), or the fixed binding pair member can be a ligand for the target receptor in the detection sample or vice versa (that is, the fixed binding pair member can be a receptor for the target ligand in the detection sample). Various supports or surface materials have been developed for these applications, and various bonding or "functionalization" techniques are needed to fix the specific binding pair member to the support / surface.

[0006] Surfaces functionalized with binding agents are usually used as basic test architectures for detecting substances. The key problems encountered in the process of functionalizing surfaces with binding agents include the need for numerous materials and resources and a large amount of time, particularly for "fine" systems. In addition, the coupling process and the resulting waste materials may be dangerous, and this is also true for some surfaces of its application. The management of each process and waste is also usually related to basic safety measures and significant costs, and may even have to be stopped due to regulatory reasons, with serious consequences for the entire business.

[0007] For example, non-magnetic latex particles (NMLP) are widely used as surfaces (also referred to as solid phases) in homogeneous immunoassays. Binding agents such as antigens or antibodies are attached to these latex beads. Attachment can be performed by chemical reactions. A non-limiting example of such attachment reactions involves the use of an azomethine reaction followed by a reduction process to which sodium cyanoborohydride (NaBH3CN) can be applied, which is a hazardous chemical compound that must be properly managed. Functionalized NMLPs and analytes of interest are combined in a multivalent manner to form aggregates that can be visualized or quantified by spectrophotometry, particularly (but not limited to) by turbidimetry or nephelometry. This change in the turbidity (or turbidity) or scattered light of the reaction mixture, which is quantified according to the analyte concentration, is the basis of homogeneous immunoagglutination assays.

[0008] Receptor proteins such as thyroid stimulating hormone receptor (TSHR) on the cell membrane surface bind specific molecules or proteins to induce physiological changes or responses. TSHR is used to detect TSI (thyroid stimulating immunoglobulin) to assist in the diagnosis of Graves' disease. These receptors are generally transmembrane proteins and difficult to purify. The purification process is often complicated and time-consuming. Purified receptor proteins are often unstable and require relatively complex buffer systems to maintain their function and stability. This makes assay development difficult and difficult to achieve.

[0009] Furthermore, attaching "delicate" binders such as the thyrotropin receptor to latex beads for immunoassays typically requires complex assay architectures with multiple components, such as (but not limited to) the use of secondary capture proteins and relatively complex buffer systems to stabilize them and maintain their functionality.

[0010] Additionally, these latex beads used in immunoassays ultimately represent waste. The waste disposal costs associated with these immunoassay reagents containing latex beads will continue to be a challenge, and the costs are likely to rise significantly in the future.

[0011] Therefore, there is a need in the art for new and improved diagnostic immunoassay reagents that overcome the deficiencies and disadvantages of the prior art. The present disclosure is directed to such reagents and kits and microfluidic devices containing the same, as well as methods of producing and using the same. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 Schematically depicts a diagram of a portion of a diagnostic reagent composition constructed according to the present disclosure. The diagnostic reagent composition comprises at least one binding agent containing a receptor domain on a liposome. The binding agent connected to the liposome via a transmembrane domain can be a genetically engineered antigen, ligand or antibody.

[0013] Figure 2Schematically depicted is a thyroid stimulating hormone receptor (TSHR) anchored in the lipid bilayer of a liposome via its transmembrane domain to form a non-limiting embodiment of a diagnostic reagent composition according to the present disclosure. The thyroid stimulating IgG (TSI) epitope is present in the extracellular domain of the receptor protein.

[0014] Figure 3 Schematic depiction of TSHR-liposomes specifically recognizing and binding to TSI (anti-TSHR monoclonal antibody) in an agglutination-like event.

[0015] Figure 4A Dynamic light scattering profiles of liposomes functionalized with TSHR (TSHR-liposomes) in the presence and absence of anti-TSHR monoclonal antibodies (TSI). The size increase observed after addition of the antibody confirms that an agglutination event has occurred.

[0016] Figure 4B Dynamic light scattering profiles of liposomes functionalized with TSHR in the presence and absence of anti-TSHR monoclonal antibody (TSI). No size increase was observed after adding the antibody to the liposomes. Therefore, there was no aggregation. This confirms Figure 4A The agglutination events shown in are specific and occur only when functionalized TSHR-liposomes are used to form immune complexes with TSI.

[0017] Figure 5 Schematically depicted are other non-limiting embodiments of the diagnostic reagent compositions constructed according to the disclosure. These embodiments include functionalized liposomes with and without dyes. This diagram illustrates the simultaneous detection of analyte A (square) and analyte B (circle) by the presence or absence of a dye in the liposome. DETAILED DESCRIPTION

[0018] Before explaining at least one embodiment of the present disclosure in detail through exemplary language and results, it should be understood that the present disclosure is not limited in its application to the construction details and component arrangements set forth in the following description. The present disclosure is capable of other embodiments, or can be practiced or carried out in various ways. As such, the language used herein is intended to be given the broadest scope and meaning; and the embodiments are intended to be exemplary-not exhaustive. In addition, it should be understood that the wording and terminology employed herein are for descriptive purposes and should not be considered limiting.

[0019] Unless otherwise defined herein, the scientific and technical terms used in conjunction with the present disclosure should have the meanings commonly understood by those of ordinary skill in the art. Further, unless the context otherwise requires, singular terms should include plural terms, and plural terms should include singular terms. The aforementioned techniques and procedures are generally performed according to conventional methods well known in the art, and as described in various general and more specific references cited and discussed throughout this specification. The nomenclature and laboratory procedures and techniques used in conjunction with analytical chemistry, synthetic organic chemistry, and medical and pharmaceutical chemistry as described herein are those well known and commonly used in the art. Standard techniques are used for chemical synthesis and chemical analysis.

[0020] All patents, published patent applications, and non-patent publications mentioned in this specification are indicative of the technical level of those skilled in the art to which the present disclosure pertains. All patents, published patent applications, and non-patent publications cited in any part of this application are expressly incorporated herein by reference in their entirety, to the same extent as if each individual patent or publication was specifically and individually indicated to be incorporated by reference.

[0021] According to the present disclosure, all articles, compositions, kits and / or methods disclosed herein can be prepared and performed without excessive experimentation. Although articles, compositions, kits and / or methods have been described according to specific embodiments, it is obvious to those skilled in the art that changes can be applied to the steps or step sequences of the articles, compositions, kits and / or methods and methods described herein without departing from the concept, spirit and scope of the present disclosure. All such similar substitutions and modifications apparent to those skilled in the art are considered to be within the spirit, scope and concept of the present disclosure as defined by the appended claims.

[0022] As utilized in accordance with this disclosure, unless otherwise indicated, the following terms shall be understood to have the following meanings:

[0023] When used in conjunction with the term "comprising" in the claims and / or specification, the term "a" or "an" may mean "one", but it is also consistent with the meaning of "one or more", "at least one", and "one or more than one". As such, unless the context clearly indicates otherwise, the terms "a", "an", and "the" include plural referents. Thus, for example, a reference to a "compound" may refer to one or more compounds, two or more compounds, three or more compounds, four or more compounds, or a greater number of compounds. The term "plurality" refers to "two or more".

[0024] The use of the term "at least one" should be understood to include one and any number more than one, including but not limited to 2, 3, 4, 5, 10, 15, 20, 30, 40, 50, 100, etc. The term "at least one" can extend up to 100 or 1000 or more, depending on the term to which it is attached; in addition, the number of 100 / 1000 is not considered limiting, as higher limits may also produce satisfactory results. In addition, the use of the term "at least one of X, Y, and Z" should be understood to include X alone, Y alone, and Z alone, as well as any combination of X, Y, and Z. For example, the use of ordinal numerical terms (i.e., "first," "second," "third," "fourth," etc.) is only for the purpose of distinguishing two or more items, and is not intended to imply any order or sequence or importance of an item over another or any order of addition.

[0025] The use of the term "or" in the claims is intended to mean the inclusive "and / or" unless explicitly stated to refer to only alternatives or unless the alternatives are mutually exclusive. For example, the condition "A or B" satisfies any of the following: A is true (or exists) and B is false (or does not exist), A is false (or does not exist) and B is true (or exists), and both A and B are true (or exist).

[0026] As used herein, any reference to "one embodiment," "an embodiment," "some embodiments," "one example," "for example," or "an example" means that a particular element, feature, structure, or characteristic described in conjunction with the embodiment is included in at least one embodiment. For example, the phrases "in some embodiments" or "an example" appearing in various places in the specification do not necessarily all refer to the same embodiment. Further, all references to one or more embodiments or examples are to be construed as non-limiting to the claims.

[0027] Throughout this application, the term "about" is used to indicate that a value includes variations in the inherent errors of the composition / instrument / device, the method used to determine the value, or the variations that exist in the object of study. For example, but not as a limitation, when the term "about" is utilized, a specified value can vary from the specified value by plus or minus 20 percent, or 15 percent, or 12 percent, or 11 percent, or 10 percent, or 9 percent, or 8 percent, or 7 percent, or 6 percent, or 5 percent, or 4 percent, or 3 percent, or 2 percent, or 1 percent, as such variations are suitable for performing the disclosed methods and as understood by those of ordinary skill in the art.

[0028] As used in this specification and claims, the words "comprising" (and any forms of comprising, such as "comprise" and "comprises"), "having" (and any forms of having, such as "have" and "has"), "including" (and any forms of including, such as "includes" and "include"), or "contain" (and any forms of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional unrecited elements or method steps.

[0029] As used herein, the term "or a combination thereof" refers to all permutations and combinations of the items listed before the term. For example, "A, B, C, or a combination thereof" is intended to include at least one of the following: A, B, C, AB, AC, BC, or ABC, and if the order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, explicitly included are combinations containing repetitions of one or more items or terms, such as BB, AAA, AAB, BBC, AAABCCCC, CBBAAA, CABABB, and the like. It will be understood by those skilled in the art that, unless otherwise apparent from the context, there is generally no limit to the number of items or terms in any combination.

[0030] As used herein, the term "substantially" means that the subsequently described event or situation occurs completely, or that the subsequently described event or situation occurs to a large extent or in scope. For example, when related to a particular event or situation, the term "substantially" means that the subsequently described event or situation occurs at least 80% of the time, or at least 85% of the time, at least 90% of the time, or at least 95% of the time. The term "substantially adjacent" can mean that two items are 100% adjacent to each other, or that two items are closely adjacent to each other, but not 100% adjacent to each other, or that a portion of one of the two items is not 100% adjacent to the other item, but is closely adjacent to the other item.

[0031] As used herein, the phrases "associated with" and "coupled with" include both direct association / binding of two moieties to each other and indirect association / binding of two moieties to each other. For example, non-limiting examples of association / coupling include covalent binding of one moiety to another moiety through a direct bond or through a spacer group, non-covalent binding of one moiety to another moiety directly or with the aid of a specific binding pair member that binds to the moiety, such as by dissolving one moiety in the other moiety or by synthesizing and coating one moiety on the other moiety, incorporating one moiety into the other moiety.

[0032] The terms "analog" and "derivative" are used interchangeably herein and refer to substances that contain in their structure the same basic carbon skeleton and carbon functionality as a given compound, but may also contain one or more substitutions therewith. As used herein, the term "substitution" is understood to refer to the replacement of at least one substituent on a compound with a residue R. In certain non-limiting embodiments, R may include H, hydroxyl, thiol, a halide selected from fluoride, chloride, bromide or iodide, a C1-C4 compound selected from one of the following: optionally substituted linear, branched or cyclic alkyl, and linear, branched or cyclic alkenyl, wherein the optional substituents are selected from one or more of alkenylalkyl, alkynylalkyl, cycloalkyl, cycloalkenylalkyl, arylalkyl, heteroarylalkyl, heterocycloalkyl, optionally substituted heterocycloalkenylalkyl, arylcycloalkyl and arylheterocycloalkyl, each of which is optionally substituted, wherein the optional substituents are selected from one or more of the following: alkenylalkyl, alkynylalkyl, cycloalkyl, cycloalkenylalkyl, arylalkyl, alkylaryl, heteroarylalkyl, heterocycloalkyl, optionally substituted heterocycloalkenylalkyl, arylcycloalkyl and arylheterocycloalkyl, phenyl, cyano, hydroxyl, alkyl, aryl, cycloalkyl, cyano, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), carboxyl and -C(O))-alkyl.

[0033] As used herein, the term "sample" should be understood to include any type of biological sample that can be utilized in accordance with the present disclosure. Examples of fluid biological samples that can be utilized include, but are not limited to, whole blood or any portion thereof (i.e., plasma or serum), urine, saliva, sputum, cerebrospinal fluid (CSF), skin, intestinal fluid, intraperitoneal fluid, cystic fluid, sweat, interstitial fluid, extracellular fluid, tears, mucus, bladder washings, semen, feces, pleural fluid, nasopharyngeal fluid, combinations thereof, and the like.

[0034] As used herein, particularly (but not by way of limitation) in the term "target analyte specific binding partner", the term "specific binding partner" should be understood to refer to any molecule capable of specifically associating with a target analyte. For example, but not by way of limitation, the binding partner may be an antibody, a receptor, a ligand, an aptamer, a molecularly imprinted polymer (i.e., an inorganic or organic matrix), a combination or derivative thereof, and any other molecule capable of specifically binding to a target analyte.

[0035] The term "antibody" is used in the broadest sense herein and refers to, for example, intact monoclonal and polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), antibody fragments and conjugates thereof that exhibit the desired biological activity for analyte binding (e.g., but not limited to Fab, Fab', F(ab')2, Fv, scFv, Fd, diabodies, single-chain antibodies, and other antibody fragments and conjugates thereof that retain at least a portion of the variable region of an intact antibody), antibody surrogate proteins or peptides (i.e., engineered binding proteins / peptides), and combinations or derivatives thereof. Antibodies can be of any type or class (e.g., IgG, IgE, IgM, IgD, and IgA) or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2).

[0036] An "analyte" is a macromolecule that is capable of being recognized by an analyte-specific binding partner, such as, but not limited to, an antibody. Both analytes and haptens contain at least one antigenic determinant or "epitope," which is a region of an antigen or hapten that binds to an analyte-specific binding partner (i.e., an antibody). Typically, an epitope on a hapten is an entire molecule.

[0037] Turning now to the inventive concept, certain non-limiting embodiments of the present disclosure relate to diagnostic reagent compositions (such as but not limited to diagnostic immunoassay reagent compositions) for detecting target analytes in biological samples. The diagnostic reagent composition comprises a liposome and at least one analyte-specific binding element associated therewith. The liposome has a lipid bilayer and an outer surface, an inner surface, and a domain (i.e., an extramembrane domain) outside the membrane. The extramembrane domain outside the membrane can reach the space on the outer surface or inner surface of the liposome. The analyte-specific binding element comprises a transmembrane domain and an extracellular / extramembrane domain, and the extracellular / extramembrane domain comprises a domain that specifically binds to the target analyte. The liposome and the analyte-specific binding element are so associated that the transmembrane domain of at least one analyte-specific binding element is anchored in the lipid bilayer of the liposome; in this way, at least a portion of the extramembrane domain of the analyte-specific binding element is exposed on the outer surface of the liposome for detecting the target analyte.

[0038] Any analyte-specific binding element known in the art or otherwise contemplated herein that can be used for diagnostic detection of analyte binding thereto can be utilized in accordance with the present disclosure. Non-limiting examples of types of analyte-specific binding elements for diagnostic use include receptors, ligands, antigens, antibodies, aptamers, molecularly imprinted polymers, and the like, as well as derivatives and variants thereof, and any combination thereof.

[0039] The analyte-specific binding elements utilized in accordance with the present disclosure can be integrally formed with transmembrane and extracellular / extramembrane domains attached to each other. Non-limiting examples of proteins or their respective parts containing transmembrane domains that can be used as analyte-specific binding elements in accordance with the present disclosure include receptor proteins or their respective parts. Specific non-limiting examples of receptor proteins and derivatives or variants thereof that can be used to detect target analytes present in biological samples in accordance with the present disclosure include at least a portion of thyroid stimulating hormone receptor (TSHR), ligand-gated ion channel receptors, enzyme-linked or kinase-linked receptors, cell matrix adhesion receptors, cell adhesion molecules, adrenergic receptors, IgG Fc receptors, glucocorticoid receptors, G protein-coupled receptors, etc., and any combination thereof.

[0040] Alternatively, analyte-specific binding elements can be produced by covalently conjugating homologous or heterologous transmembrane domains to soluble proteins / peptides or extracellular fragments of proteins / peptides. Non-limiting examples of soluble proteins / peptides (including extracellular fragments thereof) that can be conjugated to transmembrane domains include antigens, ligands, antibodies, and the like. Specific non-limiting examples of soluble proteins / peptides that can be conjugated to transmembrane domains to form analyte-specific elements for detecting target analytes present in biological samples include prostate-specific antigens, antibodies to alpha-fetoprotein, intrinsic factors, and the like, and any combination thereof.

[0041] Any heterologous transmembrane domain known in the art or otherwise contemplated herein that is capable of being conjugated to a soluble or extracellular protein / peptide can be utilized in accordance with the present disclosure. Non-limiting examples of transmembrane domains known in the art for anchoring soluble or extracellular proteins / peptides to lipids include transmembrane domains of various ion channel receptors or other types of receptors (e.g., but not limited to G protein coupled receptors (GPCRs)), transporters, and the like. In addition, transmembrane domains can also be part of pore-forming proteins in general. Non-limiting examples of pore-forming proteins with transmembrane domains that can be utilized in accordance with the present disclosure include porins, hemolysins, nucleoporins, membrane attack complexes (MAC), complement component C9, or subunits, combinations or polymers of porins, hemolysins, nucleoporins, membrane attack complexes (MAC), and complement component C9, and the like.

[0042] The liposomes of the diagnostic reagent compositions of the present disclosure can be formed by any lipid known in the art or otherwise contemplated herein, and can have any size, as long as the diagnostic reagent compositions are capable of binding to the analyte present in the biological sample, and generating a detectable signal indicating the presence and / or concentration of the target analyte in the biological sample. After binding to the analyte, the diagnostic reagent compositions may be capable of generating a detectable signal either alone (i.e., homogeneously) or via interaction with one or more other diagnostic reagents (i.e., heterogeneously).

[0043] Suitable liposomes for use in the compositions described herein include, but are not limited to, multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs), giant unilamellar vesicles (GUVs), and the like.

[0044] Non-limiting examples of liposome sizes that can be utilized in accordance with the present invention include about 20 nm, about 25 nm, about 30 nm, about 35 nm, about 40 nm, about 45 nm, about 50 nm, about 60 nm, about 70 nm, about 75 nm, about 80 nm, about 90 nm, about 100 nm, about 110 nm, about 120 nm, about 125 nm, about 130 nm, about 140 nm, about 150 nm, about 160 nm, about 170 nm, about 175 nm, about 180 nm, about 190 nm, about 200 nm, about 210 nm, about 220 nm, about 225 nm, about 230 nm, about 240 nm, about 250 nm, about 260 nm, about 270 nm, about m, about 275nm, about 280nm, about 290nm, about 300nm, about 325nm, about 350nm, about 375nm, about 400nm, about 425nm, about 450nm, about 475nm, about 500nm, about 525nm, about 550nm, about 575nm, about 600nm, about 625nm, about 650nm, about 675nm, about 700nm, about 725nm, about 750nm, about 775nm, about 800nm, about 825nm, about 850nm, about 875nm, about 900nm, about 925nm, about 950nm, about 975nm, about 1000nm, about 1225nm, about 1250nm m, about 1275nm, about 1300nm, about 1325nm, about 1350nm, about 1375nm, about 1400nm, about 1425nm, about 1450nm, about 1475nm, about 1500nm, about 1600nm, about 1700nm, about 1800nm, about 1900nm, about 2000nm, about 2100nm, about 2200nm, about 2300nm, about 2400nm, about 2500nm, about 2600nm, about 2700nm, about 2800nm, about 2900nm, about 3000nm, about 3100nm, about 3200nm, about 3300nm, about 3400nm, about 3500nm , about 3600nm, about 3700nm, about 3800nm, about 3900nm, about 4000nm, about 4100nm, about 4200nm, about 4300nm, about 4400nm, about 4500nm, about 4600nm, about 4700nm, about 4800nm, about 4900nm, about 500nm and greater, and ranges formed by any of the above values ​​(i.e., a range from about 20nm to about 5000nm, a range from about 20nm to about 1000nm, a range from about 50nm to about 1000nm, a range from about 50nm to about 500nm, a range from about 100nm to about 500nm, a range from about 100nm to about 200nm, etc.).

[0045] Non-limiting examples of lipids that can be used to produce liposomes include phospholipids such as, but not limited to, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol, and the like, and derivatives thereof and any combination thereof.

[0046] Other non-limiting examples of lipid types that can be used to produce liposomes include sphingolipids, glycerophospholipids, sterols and sterol derivatives. The non-limiting examples of sphingolipids that can be utilized include sphingomyelin and ceramides containing saturated, monounsaturated and / or polyunsaturated acyl chains of varying lengths. The non-limiting examples of phospholipids with various head groups that can be utilized include phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylinositol (PI), cardiolipin, phosphatidylserine (PS) containing saturated, monounsaturated and / or polyunsaturated acyl chains of varying lengths. Non-limiting examples of sterols and sterol derivatives that can be used include, but are not limited to, cholesterol, brassicasterol, allocholesterol, cholesterol methyl ether, campesterol, campesterol, cholesterol acetate, coprostanol, streptostanol, dehydrostreptostanol, dihydrocholesterol, dihydrolanosterol, epicholesterol, 7-enecholanol, lanosterol, dihydrositosterol, sitosterol, stigmasterol, dihydrozymosterol, zymosterol, and the like.

[0047] Mixtures of lipids can also be used, including mixtures of two or more sphingolipids, glycerophospholipids, sterols and sterol derivatives. In certain specific (but non-limiting) embodiments, sterols and sterol derivatives are not used alone to produce liposomes, but are included in mixtures with sphingolipids or glycerophospholipids. In a specific (but non-limiting) embodiment, sterols and / or sterol derivatives are present in liposomes containing sphingolipids or glycerophospholipids in the range of about 0% to about 40% of total lipids.

[0048] Specific (but non-limiting) examples of sphingolipids that can be utilized in accordance with the present disclosure include porcine brain sphingomyelin, egg sphingomyelin, and bovine milk sphingomyelin. Specific (but non-limiting) examples of glycerophospholipids that can be utilized in accordance with the present disclosure include phospholipids with various head group structures, such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylinositol (PI), cardiolipin, phosphatidylserine (PS) with the following: two saturated acyl chains of different lengths (e.g., 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-distearo ... n-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol), 1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol), 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-myo-inositol), 1,2-distearoyl-sn-glycero-3-phosphoinositol, 1′,3′-bis[1,2-dipalmitoyl-sn-glycero-3-phospho]-glycerol, 1′,3′-bis[1,2-distearoyl-sn-glycero-3-phospho]-glycerol, 1,2 -dipalmitoyl-sn-glycero-3-phospho-L-serine, 1,2-distearoyl-sn-glycero-3-phospho-L-serine), and one saturated acyl chain of varying lengths and one monounsaturated acyl chain of varying lengths (e.g., 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine, 1-stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine, 1-palmitoyl-2-oleoyl-sn-glycero- 3-phospho-(1′-rac-glycerol), 1-stearoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoinositol, 1′,3′-bis[1-palmitoyl-2-oleoyl-sn-glycero-3-phospho]-glycerol, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine, 1-stearoyl-2-oleoyl-sn-glycero-3-phospho-L-serine), and one saturated acyl chain of varying lengths and one polyunsaturated acyl chain of varying lengths (e.g.,1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine, 1-stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine, 1-stearoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine, 1-palmitoyl-2-linoleoyl-sn-glycero-3-phospho-(1′-rac-glycerol), 1-stearoyl-2-linoleoyl-sn-glycero-3-phospho-(1′-rac-glycerol), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phospho-L-serine, 1-stearoyl-2-linoleoyl-sn-glycero-3-phospho-L-serine). In certain specific (but non-limiting) examples, each fatty acid acyl chain has a range of about 16 to about 20 carbon atoms, and in particular (but not as a limitation) 16, 18 or 20 carbon atoms. The specific (but non-limiting) number of double bonds of each fatty acid acyl chain ranges from 0 to 2. Specific (but non-limiting) examples of sterols and sterol derivatives for use with liposomes containing sphingolipids or glycerophospholipids include cholesterol, dihydrocholesterol, epicholesterol, sitosterol and 7-enecholanol. Cholesterol is the most specific (but non-limiting) sterol. Specific (but non-limiting) sphingolipids and glycerophospholipids can be used alone, or in the presence of specific (but non-limiting) sterols and sterol derivatives as a mixture of sphingolipids and glycerophospholipids to form the porous liposomes described in the present disclosure. For example, in specific (but non-limiting) embodiments, the liposomes can contain 100% porcine brain sphingomyelin or a mixture of porcine brain sphingomyelin and cholesterol. In a specific (but non-limiting) example, sterols and sterol derivatives may be present in the range of about 20% to about 40% of the total lipids, such as (but not limited to) about 30%.

[0049] The diagnostic reagent composition can be provided with any element or feature, which allows the detection of the complex of liposome and the analyte combined therewith. In some specific (but non-restrictive) embodiments, the diagnostic reagent composition can have at least one dye associated therewith, to promote the detection of the combined analyte. For example (but not limited to), liposomes can have at least one dye encapsulated therein. Alternatively (and / or in addition), at least one lipid containing dye (such as but not limited to phospholipids containing dye) can be used in the production of liposomes or otherwise incorporated therein. Dye can be used for (such as but not limited to) spectrophotometry, luminescence detection (that is, chemiluminescence or fluorescence detection).

[0050] In specific (but non-limiting) embodiments, at least one biotinylated lipid (such as but not limited to a biotinylated phospholipid) may be used in the production of liposomes.

[0051] Certain non-limiting embodiments of the present disclosure relate to kits containing one or more of any diagnostic reagent compositions disclosed herein or otherwise contemplated. In certain specific (but non-limiting) embodiments, the kit further comprises at least one additional assay reagent that interacts with the diagnostic reagent composition for detecting the presence and / or concentration of a target analyte in a biological sample.

[0052] In a specific (but non-limiting) embodiment, the kit comprises two or more diagnostic reagent compositions arranged together in a single composition for performing multiplex assays for two different target analytes. In this way, the first diagnostic reagent composition and the second diagnostic reagent composition are provided with different dyes associated therewith (or other types of detection mechanisms that are different from each other), which allows detection of two target analytes in a single reaction.

[0053] The compositions / reagents of the kit can be provided in any form that allows them to function in accordance with the present disclosure. For example, but not by way of limitation, each reagent can be provided in liquid form and provided in the kit in bulk and / or in a single aliquot. Alternatively, in a specific (but non-limiting) embodiment, one or more reagents can be provided in the kit in the form of a single aliquot of a lyophilized reagent. The use of dried reagents in kits / microfluidic devices is described in detail in U.S. Patent No. 9,244,085 (Samproni), the entire contents of which are expressly incorporated herein by reference.

[0054] In addition to the compositions / reagents described in detail above herein, the kit may further contain other reagents for carrying out any specific assay described herein or otherwise considered. The properties of these additional reagents will depend on the specific assay format, and their identification is entirely within the skill of those of ordinary skill in the art; therefore, further description thereof is deemed unnecessary. In addition, depending on the cross-reactivity and stability of the compositions / reagents, the compositions / reagents present in the kit may each be located in separate containers / compartments, or various compositions / reagents may be combined in one or more containers / compartments. In addition, the kit may include a microfluidic device in which the compositions / reagents are arranged.

[0055] The relative amounts of the various compositions / reagents in the kit can vary widely to provide concentrations of compositions / reagents that substantially optimize the reactions that need to occur during the assay method and further substantially optimize the sensitivity and selectivity of the assay. Where appropriate, one or more compositions / reagents in the kit can be provided as dry powders, such as lyophilized powders, and the kit can further include excipients for dissolving the dry reagents; in this way, reagent solutions having appropriate concentrations for performing the methods or assays disclosed herein can be obtained from these compositions. Positive and / or negative controls can also be included in the kit. In addition, the kit can further include a set of written instructions explaining how to use the kit. Kits of this nature can be used in any method described herein or otherwise contemplated.

[0056] Certain other non-limiting embodiments of the present disclosure relate to a microfluidic device comprising one or more of any diagnostic reagent compositions described herein above or otherwise contemplated herein. In particular, certain non-limiting embodiments include a microfluidic device for determining the concentration of at least one target analyte in a sample. The microfluidic device comprises: (i) an inlet channel through which a sample is applied; and (ii) at least one first compartment, which is fluidically connected to the inlet channel and contains at least one diagnostic reagent composition disclosed herein or otherwise contemplated. The compartment of (ii) may further contain any additional reagents required to perform an assay for detecting a target analyte. Any assay reagent disclosed herein or otherwise contemplated may be used in the microfluidic device of the present disclosure.

[0057] The microfluidic device can be provided with any arrangement of compartments and distribution of various compositions / reagents therebetween that allows the device to function in accordance with the present disclosure. That is, when the diagnostic reagent composition is utilized in combination with a second assay reagent, the two reagents can be disposed in the same compartment or in different compartments. When the two reagents are separated between two compartments, the diagnostic reagent composition can be disposed in a first compartment in fluid communication with the inlet channel, and at least one additional assay reagent can be disposed in a second compartment in fluid communication with the first compartment.

[0058] In a specific (but non-limiting) embodiment, the microfluidic device comprises two or more of any diagnostic reagent compositions disposed together in the microfluidic device, so that multiple determinations for two different target analytes can be performed within the microfluidic device. In this way, the first diagnostic reagent composition and the second diagnostic reagent composition (and additional diagnostic reagent compositions, if present) are provided with different dyes associated therewith (or other types of detection mechanisms that are different from each other), which allow detection of two target analytes in a single reaction. Two or more diagnostic reagent compositions can be disposed in the same or separate compartments of the microfluidic device.

[0059] The microfluidic device of the present disclosure can have any design or configuration known in the art or otherwise considered herein for diagnostic analyte determination (such as but not limited to diagnostic immunoassay). In some specific (but non-limiting) embodiments, the microfluidic device can be in the form of a cartridge configured to be inserted into an automated diagnostic test instrument system for performing diagnostic determination. Alternatively, the microfluidic device can be a stand-alone product that can be read without a diagnostic test instrument system. For example (but not as a limitation), the microfluidic device can be in the form of a lateral flow device, which can be carried out in a point-of-care (POC) location.

[0060] Any compartment of a microfluidic device may be sealed to maintain a reagent disposed therein in a substantially airtight environment until it is used; for example, a compartment containing a lyophilized reagent may be sealed to prevent any accidental reconstitution of the reagent. An inlet channel and a compartment, as well as two compartments, may be described as being "capable of fluid communication" with each other; this phrase indicates that each compartment may still be sealed, but that the two compartments are capable of having fluid flow therebetween after a seal formed therein or therebetween is pierced.

[0061] The microfluidic device of the present disclosure may be provided with any other desired features known in the art or otherwise considered herein. For example, but not by way of limitation, the microfluidic device of the present disclosure may further include a reading chamber; the reading chamber may be any compartment containing the reagents described herein above, or the reading chamber may be in fluid communication with the compartment. The microfluidic device may further include one or more additional compartments containing other solutions, such as (but not limited to) washing solutions, diluting solutions, excipients, interfering solutions, positive controls, negative controls, quality controls, and the like. These additional compartments may be in fluid communication with one or more other compartments. For example, the microfluidic device may further include one or more compartments containing a washing solution, and these compartments may be in fluid communication with any other compartment of the device. In another example, the microfluidic device may further include one or more compartments containing an excipient for dissolving one or more dry reagents, and one or more compartments may be in fluid communication with any other compartment of the device. In yet another further example, the microfluidic device may include one or more compartments containing a diluting solution, and one or more compartments may be in fluid communication with any other compartment of the device.

[0062] Certain non-limiting embodiments of the present disclosure relate to methods for producing any diagnostic reagent composition disclosed herein or otherwise contemplated. In a specific (but non-limiting) embodiment, the method comprises the steps of: (1) combining any lipid disclosed herein or otherwise contemplated with at least one of any analyte-specific binding elements disclosed herein or otherwise contemplated to form a mixture; and (2) incubating the mixture under conditions leading to the formation of at least one liposome, the at least one liposome having at least one analyte-specific binding element anchored in the lipid bilayer of the liposome via a transmembrane domain of at least one analyte-specific binding element, and wherein the extracellular / extramembrane domain of the at least one analyte-specific binding element comprises a domain extending from the outer surface of the liposome for specific binding to a target analyte.

[0063] Alternatively, the liposomes can be formed prior to interacting with the analyte-specific binding element to produce the diagnostic reagent composition. Thus, in another specific (but non-limiting) embodiment, the method comprises the following steps: (1) combining at least one of any liposomes disclosed herein or otherwise contemplated with at least one of any analyte-specific binding elements disclosed herein or otherwise contemplated to form a mixture; and (2) incubating the mixture under conditions that result in at least one analyte-specific binding element being anchored in the lipid bilayer of at least one liposome via the transmembrane domain of at least one analyte-specific binding element, and wherein the extracellular / extramembrane domain of the at least one analyte-specific binding element comprises a domain extending from the outer surface of the liposome for specific binding to the target analyte.

[0064] In addition, in some non-limiting embodiments, at least one dye can be incorporated into the diagnostic reagent composition during the production method. For example (but not limited to), when lipid is mixed with analyte-specific binding element to form liposome, then at least one dye can be added to the mixture so that at least one liposome formed has at least one dye encapsulated therein. Optionally, at least one phospholipid containing dye and / or at least one biotinylated phospholipid can be used as one of the lipids mixed with analyte-specific binding element to form liposome. In an alternative, when analyte-specific binding element is mixed with preformed liposome, then at least one liposome can have at least one dye encapsulated therein, or at least one liposome can include at least one phospholipid containing dye and / or at least one biotinylated phospholipid.

[0065] Certain non-limiting embodiments of the present disclosure relate to methods for determining the presence and / or concentration of at least one target analyte in a biological sample. In the method, the biological sample is combined with at least one of any diagnostic reagent compositions disclosed herein or otherwise contemplated under conditions that allow the target analyte present in the biological sample to substantially bind to the analyte-specific binding element extending from the liposome outer surface of the diagnostic reagent composition, thereby forming a complex; then, the presence and / or concentration of the target analyte is determined based on any complex formed by any assay method known in the art.

[0066] In certain specific (but non-limiting) embodiments, the method employs a homogeneous assay format. For example (but not by way of limitation), binding of the target analyte to the diagnostic reagent composition results in agglutination, and thus no additional reagents are required for detection of the target analyte.

[0067] Alternatively, the method may utilize a heterogeneous assay format, wherein an additional reagent must be used in combination with the diagnostic reagent composition for detecting a target analyte in a biological sample. For example, but not by way of limitation, the method may utilize a heterogeneous format, such as a sandwich assay. When a second reagent must be utilized, the biological sample may be contacted with the diagnostic reagent composition and the second reagent simultaneously or in whole or in part sequentially. Additionally, the detection step of the method will involve detecting a complex comprising a diagnostic reagent composition / target analyte / second assay reagent.

[0068] Certain non-limiting embodiments of the present disclosure relate to methods for determining the presence and / or concentration of at least two target analytes in a biological sample. In this method, the biological sample is combined with at least two of any diagnostic reagent compositions disclosed herein or otherwise contemplated (i.e., a first diagnostic reagent composition and a second diagnostic reagent composition) under the following conditions: (1) allowing the first target analyte present in the biological sample to substantially bind to the analyte-specific binding element extending from the outer surface of the liposomes of the first diagnostic reagent composition, thereby forming a first complex, and (2) allowing the second target analyte present in the biological sample to substantially bind to the analyte-specific binding element extending from the outer surface of the liposomes of the second diagnostic reagent composition, thereby forming a second complex. Then, based on any first complex and second complex formed by any assay method known in the art, the presence and / or concentration of each of the first target analyte and the second target analyte is determined.

[0069] Non-limiting examples of biological samples that can be utilized according to the various methods of the present disclosure include whole blood or any portion thereof (i.e., plasma or serum), urine, saliva, sputum, cerebrospinal fluid (CSF), skin, intestinal fluid, intraperitoneal fluid, cystic fluid, sweat, interstitial fluid, extracellular fluid, tears, mucus, bladder washings, semen, feces, pleural fluid, nasopharyngeal fluid, and combinations thereof. Specific non-limiting examples include lysed whole blood cells and lysed red blood cells.

[0070] As mentioned above, when the diagnostic reagent composition is used in combination with the second reagent, the two compositions can be added simultaneously or sequentially. In addition, when two or more diagnostic reagent compositions are used in the same reaction, the two diagnostic reagent compositions can be added simultaneously or sequentially. When sequentially adding the various compositions utilized in the method, the order of addition of the compositions can vary; personnel with ordinary skills in the art can determine the specific required order in which different compositions are added to the assay. Of course, the simplest order of addition is to add all materials simultaneously and determine the resulting signal. Alternatively, each composition or composition group can be combined sequentially. In certain embodiments, an incubation step can be involved after one or more additions.

[0071] Example

[0072] Examples are provided below. However, it should be understood that the present disclosure is not limited to the specific experiments, results and laboratory procedures disclosed herein in its application. On the contrary, the examples are provided only as one of the various embodiments and are intended to be illustrative rather than exhaustive.

[0073] The present disclosure is based on the concept that liposomes provide an environmentally friendly alternative to latex beads (microplastics), and that liposomes also allow for the integration of compounds that bind to or integrate into membranes. Binding agents containing such domains can be attached to liposomes. Thus, in the diagnostic reagent compositions of the present disclosure, when such binding agents containing corresponding domains that bind to or integrate into membranes are used, the liposomes are functionalized ( Figure 1 ). The binding agent is engineered by combining an analyte-specific binding element (such as but not limited to an antigen, antibody, ligand, etc.) with a component or domain that is bound to or integrated into the membrane.

[0074] For example, the use of liposomes can allow transmembrane domain-containing receptor proteins such as the thyroid stimulating hormone receptor (TSHR) to be naturally anchored into the lipid bilayer, exposing their extracellular domains for binding in a homogeneous immunoassay format ( Figure 2 ). This arrangement mimics the natural membrane conditions of the receptor protein. Alternatively, a conjugate can be produced comprising an extracellular, analyte-specific binding domain (ie, antigen, antibody, ligand, etc.) conjugated to a transmembrane domain.

[0075] Liposomes are prepared in various sizes that cover the sizes of commonly used NMLP or latex beads. TSHR has an extracellular thyroid stimulating immunoglobulin (TSI) binding epitope. When the transmembrane domain containing TSHR is incubated with liposomes, TSHR-liposomes are formed. The functionalized vesicles (TSHR-liposomes) are then used in a homogeneous immunoagglutination assay for the detection of TSI ( Figure 3 Detectors may include, but are not limited to, spectrophotometers, nephelometers, turbidimeters, coulter counters, dynamic light scattering analyzers, flow cytometry-based systems using light scattering, and the like.

[0076] To prove this concept, liposomes (100-200 nm) were prepared, incubated with TSHR, and tested on a dynamic light scattering analyzer using a commercial TSI (anti-TSHR monoclonal antibody) ( Figure 4A and 4B ). Figure 4A The dynamic light scattering profiles of liposomes functionalized with TSHR (TSHR-liposomes) in the absence and presence of anti-TSHR monoclonal antibodies (TSI) are shown. The size increase observed only after the addition of the antibody (TSI) confirms that an agglutination event has occurred. The dynamic light scattering profiles of liposomes not functionalized with TSHR in the absence and presence of anti-TSHR monoclonal antibodies (TSI) show no size increase after the addition of the antibody to the liposomes ( Figure 4B ). Therefore, there is no agglutination. This confirms Figure 4A The aggregation events shown in are specific and occur only when functionalized TSHR-liposomes are used, such as Figure 3 The ones shown in form immune complexes with TSI.

[0077] In addition, the use of dye-encapsulated liposomes or phospholipids containing dyes enhances the visualization and detection of complexes, especially when the assay involves the formation of visible clots. These functionalized liposomes containing dyes also allow for multiplexing, i.e., the simultaneous detection of multiple analytes in a single reaction. Figure 5 As shown in , a first diagnostic reagent composition having a first dye encapsulated therein and bound to a first target square analyte (depicted as a square) can be provided in the same reaction with a second diagnostic reagent composition that binds to a second target analyte (depicted as a circle) and is detected via another dye encapsulated therein or incorporated into a liposome. An example of a multiplexed analyzer can be an instrument based on flow cytometry (i.e., a flow cytometer based on luminescence detection) or a lateral flow immunoassay device.

[0078] Functionalized liposomes, such as the TSHR liposomes described herein or generally binding agent liposomes containing a receptor domain, can replace latex beads for homogeneous immunoassays.

[0079] Liposomes allow the transmembrane domain containing receptor proteins or binding agents such as TSHR to be naturally anchored into the lipid bilayer, exposing their extracellular binding domains for immunoassays. This mimics the natural membrane conditions of the receptor protein and eliminates the need to use hazardous chemicals for attachment.

[0080] The use of dye-encapsulated liposomes or dye-containing phospholipids in the preparation of binding agent liposomes containing receptor domains can enhance visualization and detection, as well as make multiplexed assays feasible.

[0081] Non-limiting illustrative embodiments

[0082] The following is a list of non-limiting illustrative embodiments disclosed herein:

[0083] Illustrative embodiments 1. A diagnostic immunoassay reagent composition for detecting a target analyte in a biological sample, comprising: a liposome having a lipid bilayer and an outer surface; at least one analyte-specific binding element comprising a transmembrane domain and an extramembrane domain, wherein the extramembrane domain comprises a domain that specifically binds to a target analyte; and wherein the transmembrane domain of the at least one analyte-specific binding element is anchored in the lipid bilayer of the liposome, such that at least a portion of the extramembrane domain of the analyte-specific binding element is exposed on the outer surface of the liposome for detecting the target analyte.

[0084] Illustrative embodiment 2. The diagnostic reagent composition of illustrative embodiment 1, wherein the at least one analyte-specific binding element is at least one receptor protein or a portion or derivative thereof.

[0085] Illustrative embodiment 3. The diagnostic reagent composition of illustrative embodiment 2, wherein the at least one receptor protein or a portion or derivative thereof is selected from at least a portion of a thyroid stimulating hormone receptor (TSHR), a ligand-gated ion channel receptor, an enzyme-linked or kinase-linked receptor, a cell matrix adhesion receptor, a cell adhesion molecule, an adrenergic receptor, an IgG Fc receptor, a glucocorticoid receptor, a G protein-coupled receptor, and combinations thereof.

[0086] Illustrative embodiment 4. The diagnostic reagent composition of any one of illustrative embodiments 1-3, wherein the at least one analyte-specific binding element comprises a conjugate in which a domain that specifically binds to a target analyte is attached to a transmembrane domain.

[0087] Illustrative embodiment 5. The diagnostic reagent composition of illustrative embodiment 4, wherein the domain that specifically binds to the target analyte is a ligand or a portion thereof.

[0088] Illustrative embodiment 6. The diagnostic reagent composition of illustrative embodiment 4, wherein the domain that specifically binds to the target analyte is an antibody or a portion thereof.

[0089] Illustrative embodiment 7. The diagnostic reagent composition of any one of illustrative embodiments 1-6, wherein the liposome has a size ranging from about 50 nm to about 1000 nm.

[0090] Illustrative embodiment 8. The diagnostic reagent composition of illustrative embodiment 7, wherein the liposome has a size ranging from about 100 nm to about 200 nm.

[0091] Illustrative Embodiment 9. The diagnostic reagent composition of any one of Illustrative Embodiments 1-8, wherein the liposomes have at least one dye encapsulated therein.

[0092] Illustrative embodiment 10. The diagnostic reagent composition of any one of illustrative embodiments 1-9, wherein the liposome comprises at least one lipid selected from the group consisting of phospholipids, sphingolipids, glycerophospholipids, and combinations thereof.

[0093] Illustrative embodiment 11. The diagnostic reagent composition of illustrative embodiment 10, wherein the liposome further comprises at least one of a sterol or a sterol derivative.

[0094] Illustrative embodiment 12. The diagnostic reagent composition of any one of illustrative embodiments 1-11, wherein the liposomes comprise at least one phospholipid containing a dye.

[0095] Illustrative Embodiment 13. The diagnostic reagent composition of any one of Illustrative Embodiments 1-12, wherein the liposomes comprise at least one biotinylated phospholipid.

[0096] Illustrative embodiment 14. A kit comprising: at least one diagnostic reagent composition of any one of illustrative embodiments 1-13.

[0097] Illustrative embodiment 15. The kit of illustrative embodiment 14, further comprising at least one additional reagent for use in a diagnostic immunoassay.

[0098] Illustrative embodiment 16. The kit of illustrative embodiment 14 or 15, further comprising at least two diagnostic reagent compositions, and wherein the kit is used in a multiplexed assay.

[0099] Illustrative embodiment 17. A microfluidic device comprising: (i) an inlet channel through which a sample is applied; and (ii) at least one compartment capable of being fluidically connected to the inlet channel, wherein the at least one compartment comprises at least one diagnostic reagent composition of any one of illustrative embodiments 1-13.

[0100] Illustrative embodiment 18. The microfluidic device of illustrative embodiment 17, further defined as a microfluidic device for performing a multiplexed assay, and wherein (ii) comprises at least two diagnostic reagent compositions.

[0101] Illustrative embodiment 19. A method for producing a diagnostic reagent composition for detecting a target analyte in a biological sample, the method comprising the following steps: (1) combining at least one lipid with at least one analyte-specific binding element to form a mixture, wherein the at least one analyte-specific binding element comprises a transmembrane domain and an extramembrane domain, and wherein the extramembrane domain comprises a domain that specifically binds to the target analyte; and (2) incubating the mixture under conditions that result in the formation of at least one liposome, the liposome having at least one analyte-specific binding element anchored in the lipid bilayer of the liposome via the transmembrane domain of the at least one analyte-specific binding element, and wherein the extramembrane domain of the at least one analyte-specific binding element comprises a domain that extends from the outer surface of the liposome for specifically binding to the target analyte.

[0102] Illustrative embodiment 20. The method of illustrative embodiment 19, wherein the at least one analyte-specific binding element is selected from at least one receptor protein or a portion thereof, and a conjugate in which a domain that specifically binds to a target analyte is attached to a transmembrane domain.

[0103] Illustrative embodiment 21. A method according to illustrative embodiment 20, wherein: the at least one analyte-specific binding element is at least one receptor protein or a portion thereof selected from the group consisting of: at least a portion of a thyroid stimulating hormone receptor (TSHR), a ligand-gated ion channel receptor, an enzyme-linked or kinase-linked receptor, a cell matrix adhesion receptor, a cell adhesion molecule, an adrenergic receptor, an IgG Fc receptor, a glucocorticoid receptor, a G protein-coupled receptor, and a combination thereof; the at least one analyte-specific binding element is a conjugate, and the domain that specifically binds to a target analyte is a ligand or a portion thereof; or the at least one analyte-specific binding element is a conjugate, and the domain that specifically binds to a target analyte is an antibody or a portion thereof.

[0104] Illustrative embodiment 22. The method of any one of illustrative embodiments 19-21, wherein the liposomes have a size in the range of about 50 nm to about 1000 nm.

[0105] Illustrative embodiment 23. The method of illustrative embodiment 22, wherein the liposomes have a size in the range of about 100 nm to about 200 nm.

[0106] Illustrative embodiment 24. The method of any one of illustrative embodiments 19-23, wherein the at least one lipid of step (1) is selected from phospholipids, sphingolipids, glycerophospholipids, and combinations thereof.

[0107] Illustrative embodiment 25. The method of illustrative embodiment 24, wherein the at least one lipid further comprises at least one of a sterol or a sterol derivative.

[0108] Illustrative embodiment 26. The method of any one of illustrative embodiments 19-25, wherein in step (1), at least one dye is added to the mixture such that at least one liposome formed in step (2) has at least one dye encapsulated therein.

[0109] Illustrative embodiment 27. The method of any one of illustrative embodiments 19-26, wherein the at least one lipid of step (1) comprises at least one phospholipid containing a dye and / or at least one biotinylated phospholipid.

[0110] Illustrative embodiment 28. A method for producing a diagnostic reagent composition for detecting a target analyte in a biological sample, the method comprising the following steps: (1) combining at least one liposome with at least one analyte-specific binding element to form a mixture, wherein the at least one liposome has a lipid bilayer and an outer surface, wherein the at least one analyte-specific binding element comprises a transmembrane domain and an extramembrane domain, and wherein the extramembrane domain comprises a domain that specifically binds to the target analyte; and (2) incubating the mixture under conditions that cause the at least one analyte-specific binding element to be anchored in the lipid bilayer of the at least one liposome via the transmembrane domain of the at least one analyte-specific binding element, and wherein the extramembrane domain of the at least one analyte-specific binding element comprises a domain that extends from the outer surface of the liposome for specifically binding to the target analyte.

[0111] Illustrative embodiment 29. The method of illustrative embodiment 28, wherein the at least one analyte-specific binding element is selected from at least one receptor protein or a portion thereof, and a conjugate in which a domain that specifically binds to a target analyte is attached to a transmembrane domain.

[0112] Illustrative embodiment 30. The method of illustrative embodiment 29, wherein: the at least one analyte-specific binding element is at least one receptor protein or a portion thereof selected from the group consisting of: at least a portion of the thyroid stimulating hormone receptor (TSHR), a ligand-gated ion channel receptor, an enzyme-linked or kinase-linked receptor, a cell matrix adhesion receptor, a cell adhesion molecule, an adrenergic receptor, an IgG Fc receptor, a glucocorticoid receptor, a G protein-coupled receptor, and a combination thereof; the at least one analyte-specific binding element is a conjugate, and the domain that specifically binds to the target analyte is a ligand or a portion thereof; or the at least one analyte-specific binding element is a conjugate, and the domain that specifically binds to the target analyte is an antibody or a portion thereof.

[0113] Illustrative Embodiment 31. The method of any one of Illustrative Embodiments 27-30, wherein the liposomes have a size in the range of about 50 nm to about 1000 nm.

[0114] Illustrative embodiment 32. The method of illustrative embodiment 31, wherein the liposomes have a size in the range of about 100 nm to about 200 nm.

[0115] Illustrative embodiment 33. The method of any one of illustrative embodiments 27-32, wherein the liposome comprises at least one lipid selected from the group consisting of phospholipids, sphingolipids, glycerophospholipids, and combinations thereof.

[0116] Illustrative embodiment 34. The method of illustrative embodiment 33, wherein the liposome further comprises at least one of a sterol or a sterol derivative.

[0117] Illustrative embodiment 35. The method of any one of illustrative embodiments 27-34, wherein the at least one liposome has at least one dye encapsulated therein.

[0118] Illustrative embodiment 36. The method of any one of illustrative embodiments 27-35, wherein the at least one liposome comprises at least one phospholipid containing a dye and / or at least one biotinylated phospholipid.

[0119] Illustrative embodiment 37. A method for determining the presence and / or concentration of a target analyte in a biological sample, the method comprising the steps of: combining the biological sample with at least one diagnostic reagent composition of any one of illustrative embodiments 1-13 under conditions that allow at least one analyte-specific binding element to bind to a target analyte present in the sample to form a complex; and determining the presence and / or concentration of the target analyte based on any complex formed.

[0120] Illustrative embodiment 38. The method of illustrative embodiment 37, wherein the method comprises a homogeneous assay format.

[0121] Illustrative embodiment 39. The method of illustrative embodiment 38, wherein the assay format comprises an agglutination assay.

[0122] Illustrative embodiment 40. The method of any one of illustrative embodiments 37-39, wherein the method comprises a heterogeneous assay format.

[0123] Illustrative Embodiment 41. The method of Illustrative Embodiment 40, wherein the assay format comprises a sandwich assay.

[0124] Illustrative embodiment 42. A method for determining the presence and / or concentration of at least two target analytes in a biological sample, the method comprising the following steps: combining the biological sample with a first diagnostic reagent composition of any one of illustrative embodiments 1-13 and a second diagnostic reagent composition of any one of illustrative embodiments 1-13 under conditions that allow the analyte-specific binding element of the first diagnostic reagent composition to bind to the first target analyte present in the sample to form a first complex, and allow the analyte-specific binding element of the second diagnostic reagent composition to bind to the second target analyte present in the sample to form a second complex; determining the presence and / or concentration of the first target analyte based on any first complexes formed; and determining the presence and / or concentration of the second target analyte based on any second complexes formed.

[0125] Therefore, according to the present disclosure, compositions, kits and devices that fully meet the goals and advantages set forth above, as well as methods of producing and using the same, have been provided. Although the present disclosure has been described in conjunction with the specific figures, experiments, results and language set forth above, it is apparent that many substitutions, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to encompass all such substitutions, modifications and variations that fall within the spirit and broad scope of the present disclosure.

Claims

1. A diagnostic immunoassay reagent composition for detecting a target analyte in a biological sample, comprising: Liposomes have a lipid bilayer and an outer surface; at least one analyte-specific binding element comprising a transmembrane domain and an extramembrane domain, wherein the extramembrane domain comprises a domain that specifically binds to a target analyte; and The transmembrane domain of the at least one analyte-specific binding element is anchored in the lipid bilayer of the liposome, so that at least a portion of the extramembrane domain of the analyte-specific binding element is exposed on the outer surface of the liposome for detecting the target analyte.

2. The diagnostic reagent composition according to claim 1, wherein the at least one analyte-specific binding member is at least one receptor protein or a portion or derivative thereof.

3. The diagnostic reagent composition according to claim 2, wherein the at least one receptor protein or a portion or derivative thereof is selected from at least a portion of a thyroid stimulating hormone receptor (TSHR), a ligand-gated ion channel receptor, an enzyme-linked or kinase-linked receptor, a cell matrix adhesion receptor, a cell adhesion molecule, an adrenergic receptor, an IgG Fc receptor, a glucocorticoid receptor, a G protein-coupled receptor, and a combination thereof.

4. The diagnostic reagent composition of claim 1, wherein the at least one analyte-specific binding element comprises a conjugate in which a domain that specifically binds to a target analyte is attached to a transmembrane domain. The diagnostic reagent composition according to claim 4 , wherein the domain that specifically binds to the target analyte is a ligand or a portion thereof. The diagnostic reagent composition according to claim 4 , wherein the domain that specifically binds to the target analyte is an antibody or a portion thereof.

7. The diagnostic reagent composition of claim 1, wherein the liposome has a size ranging from about 50 nm to about 1000 nm.

8. The diagnostic reagent composition of claim 7, wherein the liposome has a size ranging from about 100 nm to about 200 nm.

9. The diagnostic reagent composition of claim 1, wherein the liposomes have at least one dye encapsulated therein.

10. The diagnostic reagent composition according to claim 1, wherein the liposome comprises at least one lipid selected from the group consisting of phospholipids, sphingolipids, glycerophospholipids and combinations thereof.

11. The diagnostic reagent composition according to claim 10, wherein the liposome further comprises at least one of a sterol or a sterol derivative.

12. The diagnostic reagent composition of claim 1, wherein the liposomes comprise at least one phospholipid containing a dye.

13. The diagnostic reagent composition of claim 1, wherein the liposome comprises at least one biotinylated phospholipid.

14. A kit comprising: At least one diagnostic reagent composition according to any one of claims 1-13.

15. The kit of claim 14, further comprising at least one additional reagent for use in a diagnostic immunoassay.

16. The kit of claim 14, further comprising at least two diagnostic reagent compositions, and wherein the kit is used in a multiplexed assay.

17. A microfluidic device comprising: (i) an inlet channel through which a sample is applied; and (ii) at least one compartment capable of being in fluid communication with the inlet channel, wherein the at least one compartment comprises at least one diagnostic reagent composition according to any one of claims 1-13.

18. The microfluidic device of claim 17, further defined as a microfluidic device for performing a multiplexed assay, and wherein (ii) comprises at least two diagnostic reagent compositions.

19. A method for producing a diagnostic reagent composition for detecting a target analyte in a biological sample, the method comprising the steps of: (1) combining at least one lipid with at least one analyte-specific binding element to form a mixture, wherein the at least one analyte-specific binding element comprises a transmembrane domain and an extramembrane domain, and wherein the extramembrane domain comprises a domain that specifically binds to a target analyte; and (2) incubating the mixture under conditions that result in the formation of at least one liposome having at least one analyte-specific binding element anchored in the lipid bilayer of the liposome via the transmembrane domain of the at least one analyte-specific binding element, and wherein the extramembrane domain of the at least one analyte-specific binding element comprises a domain extending from the outer surface of the liposome for specific binding to the target analyte.

20. The method of claim 19, wherein the at least one analyte-specific binding element is selected from at least one receptor protein or a portion thereof, and a conjugate in which a domain that specifically binds to a target analyte is attached to a transmembrane domain.

21. The method of claim 20, wherein: The at least one analyte-specific binding element is at least one receptor protein or a portion thereof selected from the group consisting of at least a portion of a thyroid stimulating hormone receptor (TSHR), a ligand-gated ion channel receptor, an enzyme-linked or kinase-linked receptor, a cell matrix adhesion receptor, a cell adhesion molecule, an adrenergic receptor, an IgG Fc receptor, a glucocorticoid receptor, a G protein-coupled receptor, and combinations thereof; The at least one analyte-specific binding element is a conjugate, and the domain that specifically binds to the target analyte is a ligand or a portion thereof; or The at least one analyte-specific binding element is a conjugate and the domain that specifically binds to the target analyte is an antibody or a portion thereof.

22. The method of claim 19, wherein the liposomes have a size ranging from about 50 nm to about 1000 nm.

23. The method of claim 22, wherein the liposomes have a size ranging from about 100 nm to about 200 nm.

24. The method according to claim 19, wherein the at least one lipid in step (1) is selected from phospholipids, sphingolipids, glycerophospholipids and combinations thereof.

25. The method of claim 24, wherein the at least one lipid further comprises at least one of a sterol or a sterol derivative.

26. The method of claim 19, wherein in step (1), at least one dye is added to the mixture such that at least one liposome formed in step (2) has the at least one dye encapsulated therein.

27. The method of claim 19, wherein the at least one lipid of step (1) comprises at least one phospholipid containing a dye and / or at least one biotinylated phospholipid.

28. A method for producing a diagnostic reagent composition for detecting a target analyte in a biological sample, the method comprising the steps of: (1) combining at least one liposome with at least one analyte-specific binding element to form a mixture, wherein the at least one liposome has a lipid bilayer and an outer surface, wherein the at least one analyte-specific binding element comprises a transmembrane domain and an extramembrane domain, and wherein the extramembrane domain comprises a domain that specifically binds to a target analyte; and (2) incubating the mixture under conditions that result in at least one analyte-specific binding element being anchored in the lipid bilayer of at least one liposome via the transmembrane domain of the at least one analyte-specific binding element, and wherein the extramembrane domain of the at least one analyte-specific binding element comprises a domain extending from the outer surface of the liposome for specific binding to a target analyte.

29. The method of claim 28, wherein the at least one analyte-specific binding element is selected from at least one receptor protein or a portion thereof, and a conjugate in which a domain that specifically binds to a target analyte is attached to a transmembrane domain.

30. The method of claim 29, wherein: The at least one analyte-specific binding element is at least one receptor protein or a portion thereof selected from the group consisting of at least a portion of a thyroid stimulating hormone receptor (TSHR), a ligand-gated ion channel receptor, an enzyme-linked or kinase-linked receptor, a cell matrix adhesion receptor, a cell adhesion molecule, an adrenergic receptor, an IgG Fc receptor, a glucocorticoid receptor, a G protein-coupled receptor, and combinations thereof; The at least one analyte-specific binding element is a conjugate, and the domain that specifically binds to the target analyte is a ligand or a portion thereof; or The at least one analyte-specific binding element is a conjugate and the domain that specifically binds to the target analyte is an antibody or a portion thereof.

31. The method of claim 27, wherein the liposomes have a size ranging from about 50 nm to about 1000 nm.

32. The method of claim 31, wherein the liposomes have a size ranging from about 100 nm to about 200 nm.

33. The method of claim 27, wherein the liposome comprises at least one lipid selected from the group consisting of phospholipids, sphingolipids, glycerophospholipids, and combinations thereof.

34. The method of claim 33, wherein the liposome further comprises at least one of a sterol or a sterol derivative.

35. The method of claim 27, wherein the at least one liposome has at least one dye encapsulated therein.

36. The method of claim 27, wherein the at least one liposome comprises at least one phospholipid containing a dye and / or at least one biotinylated phospholipid.

37. A method for determining the presence and / or concentration of a target analyte in a biological sample, the method comprising the steps of: combining a biological sample with at least one diagnostic reagent composition according to any one of claims 1 to 13 under conditions that allow binding of at least one analyte-specific binding element to a target analyte present in the sample to form a complex; and The presence and / or concentration of the target analyte is determined based on any complexes formed.

38. The method of claim 37, wherein the method comprises a homogeneous assay format.

39. The method of claim 38, wherein the assay format comprises an agglutination assay.

40. The method of claim 37, wherein the method comprises a heterogeneous assay format.

41. The method of claim 40, wherein the assay format comprises a sandwich assay.

42. A method for determining the presence and / or concentration of at least two target analytes in a biological sample, the method comprising the steps of: combining a biological sample with a first diagnostic reagent composition according to any one of claims 1 to 13 and a second diagnostic reagent composition according to any one of claims 1 to 13 under conditions that allow the analyte-specific binding member of the first diagnostic reagent composition to bind to a first target analyte present in the sample to form a first complex, and allow the analyte-specific binding member of the second diagnostic reagent composition to bind to a second target analyte present in the sample to form a second complex; determining the presence and / or concentration of a first target analyte based on any first complex formed; and The presence and / or concentration of the second target analyte is determined based on any second complex formed.